Zacks Investment Research highlights Dentsply Sirona (XRAY) as a potentially undervalued stock, citing its 'A' grade in Value and a Zacks Rank of #2 (Buy). XRAY's P/E ratio of 8.51 is significantly lower than the industry average of 16.54, and its PEG ratio of 1.15 is also below the industry's 1.77, suggesting strong value relative to its growth prospects; additional metrics such as P/B, P/S, and P/CF ratios further support the undervaluation thesis.
Dentsply Sirona (XRAY) is presented by Zacks Investment Research as a potentially undervalued stock, meriting a Zacks Rank of #2 (Buy) and an 'A' grade for Value. The company's current Price-to-Earnings (P/E) ratio of 8.51 is substantially lower than the industry average of 16.54, and its Forward P/E has ranged between 6.77 and 12.99 over the past year, with a median of 10.10. Furthermore, XRAY's Price/Earnings-to-Growth (PEG) ratio stands at 1.15, below the industry average of 1.77, and its median PEG over the last year was 1.11. Other key valuation metrics also indicate potential undervaluation: its Price-to-Book (P/B) ratio is 1.64 compared to the industry's 4.43 (median P/B over past year was 1.66); its Price-to-Sales (P/S) ratio is 0.88 versus the industry's 1.47; and its Price-to-Cash Flow (P/CF) ratio is 15.94, slightly under the industry average of 17.38 (median P/CF over past year was 11.85). According to the analysis, these metrics, combined with a strong earnings outlook, suggest Dentsply Sirona may be trading below its intrinsic value.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
